구독하기
연구 모델
서비스
전임상 효능 평가
Resource
B6-hANG2 (ANGPT2) Mouse
제품 견적 요청
카탈로그에서 제품을 선택하여 요청을 제출해 주세요. Cyagen 팀이 상세 정보를 제공해 드립니다.
B6-hANG2 (ANGPT2) Mouse
제품명
B6-hANG2 (ANGPT2) Mouse
제품 ID
C001615
품종 계통
C57BL/6JCya-Angpt2tm1(hANGPT2)/Cya
Backgroud
C57BL/6JCya
상태
이 마우스 계통을 논문에서 사용할 경우, “B6-hANG2 (ANGPT2) Mouse (카탈로그 번호 C001615)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
HUGO-GT Humanized Models
Tumor Target Humanized Mouse Models
Cytokine Gene Humanized Mouse Models
Age-related Macular Degeneration, AMD
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
가격 문의
HUGO-GT Humanized Models
Tumor Target Humanized Mouse Models
Cytokine Gene Humanized Mouse Models
Age-related Macular Degeneration, AMD
기본 정보
검증 데이터
관련 자료
기본 정보
유전자명
유전자 별칭
ANG2, AGPT2, LMPHM10
NCBI ID
염색체
Chr 8
MGI ID
Datasheet
품종 계통 설명
Angiopoietin-2 (ANG2/ANGPT2), encoded by the ANGPT2 gene, is a secreted glycoprotein of the angiopoietin family predominantly expressed in vascular endothelial cells and stored in Weibel-Palade bodies for rapid release. ANGPT2 regulates vascular biology in a context-dependent manner by binding to the Tie2 tyrosine kinase receptor, playing pivotal roles in angiogenesis and vascular remodeling [1]. Its molecular structure includes a coiled-coil domain facilitating oligomerization and a fibrinogen-like domain critical for receptor binding. Functionally, ANGPT2 acts as a partial Tie2 receptor antagonist to Angiopoietin-1 (ANG1). Through competitive inhibition of Tie2 signaling, ANGPT2 disrupts vascular endothelial homeostasis, inducing increased vascular permeability and structural plasticity. In synergy with vascular endothelial growth factor (VEGF), ANGPT2 drives angiogenic sprouting and pathological neovascularization. Conversely, under conditions of low or absent VEGF, it mediates vascular regression [2-3]. ANGPT2 plays a central pathological role in vascular proliferative diseases such as tumor angiogenesis, diabetic retinopathy, and age-related macular degeneration. Endothelial cell activation and inflammatory responses mediated by ANGPT2 also contribute to the pathogenesis of inflammatory conditions, including sepsis and rheumatoid arthritis [4]. Therapeutic strategies targeting ANGPT2 include monoclonal antibodies (e.g., Nesvacumab) and peptide-Fc fusion proteins (e.g., Trebananib), often combined with VEGF inhibitors to enhance anti-angiogenic efficacy [5-6]. Current research efforts are focused on optimizing ANGPT2/VEGF dual-target inhibition strategies and developing biomarkers, aiming to improve clinical outcomes in tumors and ocular vascular diseases and validate its translational value as a therapeutic target in vascular and inflammatory diseases [7-8].
B6-hANG2(ANGPT2) mouse model was generated using gene editing technology to replace the entire sequence of the mouse Angpt2 gene with the human ANGPT2 gene sequence, achieving stable expression of human ANGPT2 protein. This model is suitable for studying tumorigenesis, vascular hyperproliferative diseases (e.g., diabetic retinopathy, age-related macular degeneration), autoimmune disorders, and preclinical evaluation of human ANGPT2-targeted therapeutics.
Reference
Hu B, Cheng SY. Angiopoietin-2: development of inhibitors for cancer therapy. Curr Oncol Rep. 2009 Mar;11(2):111-6.
Parikh SM. Angiopoietins and Tie2 in vascular inflammation. Curr Opin Hematol. 2017 Sep;24(5):432-438.
Leppänen VM, Saharinen P, Alitalo K. Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization. Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4376-4381.
Sha L, Zhao Y, Li S, Wei D, Tao Y, Wang Y. Insights to Ang/Tie signaling pathway: another rosy dawn for treating retinal and choroidal vascular diseases. J Transl Med. 2024 Oct 4;22(1):898.
Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opin Investig Drugs. 2019 Oct;28(10):861-869.
Gourley C. Trebananib: an alternative anti-angiogenic strategy. Lancet Oncol. 2014 Jul;15(8):776-7.
Chen-Li G, Martinez-Archer R, Coghi A, Roca JA, Rodriguez FJ, Acaba-Berrocal L, Berrocal MH, Wu L. Beyond VEGF: Angiopoietin-Tie Signaling Pathway in Diabetic Retinopathy. J Clin Med. 2024 May 9;13(10):2778.
Liu N, Liu M, Fu S, Wang J, Tang H, Isah AD, Chen D, Wang X. Ang2-Targeted Combination Therapy for Cancer Treatment. Front Immunol. 2022 Jul 8;13:949553.
변형 전략
The mouse Angpt2 gene sequence (from the ATG start codon to the TAA stop codon) was fully replaced with the corresponding human ANGPT2 gene sequence.

Figure 1. Gene editing strategy of B6-hANG2(ANGPT2) mice.
응용 분야
Mechanistic studies of tumorigenesis and cancer progression;
Pathogenesis of vascular diseases and autoimmune disorders;
Development, screening, and preclinical pharmacodynamic evaluation of human ANGPT2-targeted therapeutics.
검증 데이터
관련 자료
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
